HOUSE_OVERSIGHT_024760.jpg
1.1 MB
Extraction Summary
0
People
12
Organizations
1
Locations
0
Events
0
Relationships
2
Quotes
Document Information
Type:
Financial report / investment report
File Size:
1.1 MB
Summary
This document is page 124 of a 'Cannabis Investment Report' dated December 2017, produced by Ackrell Capital. It contains financial tables listing market data (stock price, market value, enterprise value, revenue, EBITDA) for various cannabis-related companies listed on Nasdaq, NYSE, and AMEX as of November 30, 2017. The document bears a 'HOUSE_OVERSIGHT_024760' stamp, indicating it is part of a larger production of documents to the House Oversight Committee.
Organizations (12)
| Name | Type | Context |
|---|---|---|
| Ackrell Capital, LLC |
Investment firm issuing the report
|
|
| House Oversight Committee |
Indicated by the 'HOUSE_OVERSIGHT' stamp
|
|
| Cara Therapeutics, Inc. |
Nasdaq listed cannabis-related company
|
|
| GW Pharmaceuticals plc |
Nasdaq listed cannabis-related company
|
|
| INSYS Therapeutics, Inc. |
Nasdaq listed cannabis-related company
|
|
| Zynerba Pharmaceuticals, Inc. |
Nasdaq listed cannabis-related company
|
|
| 22nd Century Group, Inc. |
AMEX listed cannabis-related company
|
|
| India Globalization Capital, Inc. |
AMEX listed cannabis-related company
|
|
| Innovative Industrial Properties, Inc. |
NYSE listed cannabis-related company
|
|
| Constellation Brands, Inc. |
NYSE listed ancillary company
|
|
| The Scotts Miracle-Gro Company |
NYSE listed ancillary company
|
|
| S&P Global Market Intelligence |
Provider of the financial data
|
Locations (1)
| Location | Context |
|---|---|
|
Location of NYSE and AMEX exchanges implied
|
Full Extracted Text
Complete text extracted from the document (2,282 characters)
ACKRELL
CAPITAL
Cannabis Investment Report | December 2017
CAPITAL
Cannabis Investment Report | December 2017
Nasdaq
($U.S. millions, except stock price)
($U.S. millions, except stock price)
Company Ticker Stock Price 11/30/17 % Below 52-Week High Market Value Enterprise Value (EV) LTM Revenue LTM EBITDA LTM EV Multiples Revenue EBITDA Forward Revenue Multiples 2018 2019 Forward EBITDA Multiples 2018 2019
Cara Therapeutics, Inc. NasdaqGM:CARA $12.45 56.3% $406.0 $303.0 $0.9 -$65.8 NM NM NM 86.1x NM NM
GW Pharmaceuticals plc NasdaqGM:GWPH 124.49 9.1% 3,153.2 2,847.7 11.0 -191.6 NM NM NM 11.4 NM NM
INSYS Therapeutics, Inc. NasdaqGM:INSY 5.30 64.7% 388.6 266.9 164.1 -35.6 1.6x NM 1.7x 1.4 NM 6.4x
Zynerba Pharmaceuticals, Inc. NasdaqGM:ZYNE 13.77 46.9% 186.6 120.4 0.0 -31.2 NM NM NM NM NM NM
Median 51.6% $397.3 $285.0 $6.0 -$50.7 1.6x NM 1.7x 11.4x NM 6.4x
GW Pharmaceuticals plc NasdaqGM:GWPH 124.49 9.1% 3,153.2 2,847.7 11.0 -191.6 NM NM NM 11.4 NM NM
INSYS Therapeutics, Inc. NasdaqGM:INSY 5.30 64.7% 388.6 266.9 164.1 -35.6 1.6x NM 1.7x 1.4 NM 6.4x
Zynerba Pharmaceuticals, Inc. NasdaqGM:ZYNE 13.77 46.9% 186.6 120.4 0.0 -31.2 NM NM NM NM NM NM
Median 51.6% $397.3 $285.0 $6.0 -$50.7 1.6x NM 1.7x 11.4x NM 6.4x
New York Stock Exchange and NYSE American
($U.S. millions, except stock price)
($U.S. millions, except stock price)
Company Ticker Stock Price 11/30/17 % Below 52-Week High Market Value Enterprise Value (EV) LTM Revenue LTM EBITDA LTM EV Multiples Revenue EBITDA Forward Revenue Multiples 2018 2019 Forward EBITDA Multiples 2018 2019
22nd Century Group, Inc. AMEX:XXII $2.33 33.4% $287.9 $273.2 $14.0 -$11.3 19.5x NM 12.7x 10.7x NM NM
India Globalization Capital, Inc. AMEX:IGC 0.58 27.6% 16.3 18.2 0.6 -1.6 28.8 NM NA NA NA NA
Innovative Industrial Properties, Inc. NYSE:IIPR 18.15 11.5% 63.5 41.3 4.6 -1.2 9.0 NM 2.4 1.3 3.7x 1.6x
Median 27.6% $63.5 $41.3 $4.6 -$1.6 19.5x NM 7.6x 6.0x 3.7x 1.6x
India Globalization Capital, Inc. AMEX:IGC 0.58 27.6% 16.3 18.2 0.6 -1.6 28.8 NM NA NA NA NA
Innovative Industrial Properties, Inc. NYSE:IIPR 18.15 11.5% 63.5 41.3 4.6 -1.2 9.0 NM 2.4 1.3 3.7x 1.6x
Median 27.6% $63.5 $41.3 $4.6 -$1.6 19.5x NM 7.6x 6.0x 3.7x 1.6x
Ancillary
Constellation Brands, Inc. NYSE:STZ $217.59 4.2% $42,572.2 $51,393.3 $7,458.5 $2,709.3 6.9x 19.0x 6.7x 6.3x 18.3x 16.6x
The Scotts Miracle-Gro Company NYSE:SMG 98.90 3.5% 5,689.7 6,969.0 2,642.1 500.0 2.6 13.9 2.5 2.4 12.9 12.0
Median 3.9% $24,131.0 $29,181.2 $5,050.3 $1,604.7 4.8x 16.5x 4.6x 4.3x 15.6x 14.3x
Constellation Brands, Inc. NYSE:STZ $217.59 4.2% $42,572.2 $51,393.3 $7,458.5 $2,709.3 6.9x 19.0x 6.7x 6.3x 18.3x 16.6x
The Scotts Miracle-Gro Company NYSE:SMG 98.90 3.5% 5,689.7 6,969.0 2,642.1 500.0 2.6 13.9 2.5 2.4 12.9 12.0
Median 3.9% $24,131.0 $29,181.2 $5,050.3 $1,604.7 4.8x 16.5x 4.6x 4.3x 15.6x 14.3x
Source: S&P Global Market Intelligence. Not Meaningful (NM) used for negative multiples, and for revenue multiples greater than 100.0x and EBITDA multiples greater than 50.0x. Not Available (NA) used for information that is not available. Enterprise Value is defined as Market Value plus Debt minus Cash and Cash Equivalents. LTM is Last Twelve Months. EBITDA is defined as Earnings Before Interest, Taxes, Depreciation and Amortization.
124 © 2017 Ackrell Capital, LLC | Member FINRA / SIPC
HOUSE_OVERSIGHT_024760
HOUSE_OVERSIGHT_024760
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document